Reseach and Development
We have compiled a collection of important resources to help you stay informed on the latest news and developments regarding the Mpox viral disease.
Scientific Publications
-
Mpox: An Overview of Pathogenesis, Diagnosis, and Public Health Implications (Branda et al., 2024)
-
Clinical spectrum and long-term outcomes of mpox: a cohort study spanning from acute infection to six-month follow-up (Zeyen et al., 2024)
-
Clade I–Associated Mpox Cases Associated with Sexual Contact, the Democratic Republic of the Congo (Kinbungo et al., 2024)
European Trial into Mpox Infection
Sponsor: University Medical Center Utrecht, the Netherlands
Summary: This is a randomized, placebo-controlled, double-blind trial to evaluate whether tecovirimat is an efficient and safe antiviral in the treatment of monkeypox in adults and adolescents (14 years old and older).
SIGA
Phase 4
Antiviral
Registered Clinical Trials for Mpox Prevention and Treatment.
European Trial into Mpox Infection
Sponsor: University Medical Center Utrecht, the Netherlands
Summary: This is a randomized, placebo-controlled, double-blind trial to evaluate whether tecovirimat is an efficient and safe antiviral in the treatment of monkeypox in adults and adolescents (14 years old and older).
Tecovirimat for Treatment of Monkeypox Virus
Sponsor: National Institute of Allergy and Infectious Diseases
Summary:This is a randomized, placebo-controlled, double-blind study to test the antiviral drug tecovirimat for the treatment of adults and children with laboratory-confirmed monkeypox virus (MPXV) disease in combination with standard of care at participating sites in the Democratic Republic of Congo.
Tecovirimat in Non-hospitalized Patients with Monkeypox
Sponsor: McGill University Health Centre
Summary: This is a multi-centre, randomized, placebo-controlled trial to evaluate the efficacy and safety of Tecovirimat in non-hospitalized patients with presumptive or PCR confirmed monkeypox infection in Canada.
Study of Tecovirimat for Human Mpox Virus
Sponsor: National Institute of Allergy and Infectious Diseases
Summary: This is a randomized, placebo-controlled, double-blind study to establish the efficacy of tecovirimat for the treatment of people with laboratory-confirmed or presumptive HMPXV disease.
Assessment of the Efficacy and Safety of Tecovirimat in Patients with Monkeypox Virus Disease
Sponsor: National Agency for AIDS Research
Summary: This is a randomized, placebo-controlled, double-blind trial to evaluate whether tecovirimat is an efficient and safe antiviral in the treatment of monkeypox in adults and adolescents (14 years old and older).